Obesity Surgery

, Volume 19, Issue 8, pp 1077–1083 | Cite as

Surgery for Nonobese Type 2 Diabetic Patients: An Interventional Study with Duodenal–Jejunal Exclusion

  • Bruno GelonezeEmail author
  • Sylka R. Geloneze
  • Carla Fiori
  • Christiane Stabe
  • Marcos A. Tambascia
  • Elinton A. Chaim
  • Brenno D. Astiarraga
  • Jose Carlos Pareja
Clinical Research



A 24-week interventional prospective trial was performed to compare the benefits of open duodenal–jejunal exclusion surgery (GJB) with a matched control group on standard medical care.


One-hundred eighty patients were screened for the surgical approach. Twelve patients accepted to be operated and presented the full eligibility criteria for surgery that includes overweight BMI (25–29.9 kg/m2), T2DM diagnosis for less than 15 years, insulin-treated patients, no history of major complications, preserved beta-cell function, and absence of autoimmunity. A matched control group (CG) of patients whom refused surgical treatment was placed to receive standard care. Patients had age of 50 (5) years, time of diagnosis 9 years (range, 3 to 15 years), time of insulin usage 6 months (range, 3 to 48 months), fasting glucose (FG), 9.8 (2.5) mg/dL, and glycated hemoglobin (A1C) 8.90 (2.12)%.


At 24 weeks after surgery, patients experienced greater reductions on FG (14% vs. 7% on CG), A1C (from 8.78 to 7.84 in GJB—p < 0.01 and 8.93 to 8.71 in CG; p < 0.05 between groups) and reductions on average daily insulin requirement (93% vs. 29%, p < 0.01). Ten patients stopped insulin usage in GJB but they remain taking oral medications. No differences were observed in both groups regarding BMI, body distribution and composition, blood pressure, and lipids.


In conclusion, duodenal–jejunal exclusion was an effective treatment for nonobese T2DM subjects. GJB was superior to standard care in achieving better glycemic control along with reduction in insulin requirements.


Metabolic surgery Type 2 diabetes Insulin therapy Incretin Insulin resistance Duodenal–jejunal exclusion Diabetes surgery 


  1. 1.
    Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med. 2007;24:451–63.CrossRefGoogle Scholar
  2. 2.
    Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–7.CrossRefGoogle Scholar
  3. 3.
    Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19:477–90.CrossRefGoogle Scholar
  4. 4.
    Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004;53(Suppl 3):S26–33.CrossRefGoogle Scholar
  5. 5.
    Donath MY, Schumann DM, Faulenbach M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(Suppl 2):S161–4.CrossRefGoogle Scholar
  6. 6.
    Knop F, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state? Diabetes. 2007;56:1951–9.CrossRefGoogle Scholar
  7. 7.
    Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002;236:554–9.CrossRefGoogle Scholar
  8. 8.
    Geloneze B, Tambascia MA, Pareja JC, et al. The insulin tolerance test in morbidly obese patients undergoing bariatric surgery. Obes Res. 2001;9:763–9.CrossRefGoogle Scholar
  9. 9.
    Cummings DE, Flum DR. Gastrointestinal surgery as a treatment for diabetes. JAMA. 2008;299:341–3.PubMedGoogle Scholar
  10. 10.
    Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.CrossRefGoogle Scholar
  11. 11.
    Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–31.CrossRefGoogle Scholar
  12. 12.
    Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1–11.CrossRefGoogle Scholar
  13. 13.
    Pacheco D, de Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007;194:221–4.CrossRefGoogle Scholar
  14. 14.
    Malerbi D, Damiani D, Rassi N, et al. Brazilian Diabetes Society consensus statement—intensive insulin therapy and insulin pump therapy. Arq Bras Endocrinol Metabol. 2006;50:125–35.CrossRefGoogle Scholar
  15. 15.
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–72.CrossRefGoogle Scholar
  16. 16.
    Ellis KJ, Bell SJ, Chertow GM, et al. Bioelectrical impedance methods in clinical research: a follow-up to the NIH Technology Assessment Conference. Nutrition. 1999;15:874–80.CrossRefGoogle Scholar
  17. 17.
    Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care. 2007;30:2399–2400.CrossRefGoogle Scholar
  18. 18.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefGoogle Scholar
  19. 19.
    Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608–15.CrossRefGoogle Scholar
  20. 20.
    Morínigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 2006;16:1594–601.CrossRefGoogle Scholar
  21. 21.
    Moses LE. Measuring effects without randomized trials? Options, problems, challenges. Med Care. 1995;33(4 Suppl):AS8–14.PubMedGoogle Scholar
  22. 22.
    Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3(2):195–7.CrossRefGoogle Scholar
  23. 23.
    Action to Control Cardiovascular Risk in Diabetes study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. The action to control cardiovascular risk in diabetes study group. N Engl J Med. 2008;358:2545–59.CrossRefGoogle Scholar
  24. 24.
    Deitel M. Surgery for diabetes at lower BMI: Some caution. Obes Surg. 2008;18(10):1211–4.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Bruno Geloneze
    • 1
    • 2
    Email author
  • Sylka R. Geloneze
    • 1
  • Carla Fiori
    • 1
  • Christiane Stabe
    • 1
  • Marcos A. Tambascia
    • 1
    • 2
  • Elinton A. Chaim
    • 1
    • 3
  • Brenno D. Astiarraga
    • 1
  • Jose Carlos Pareja
    • 1
    • 2
    • 3
  1. 1.LIMED, Laboratory of Investigation on Metabolism and MetabolismState University of Campinas, UNICAMPCampinasBrazil
  2. 2.National Institute of Science and Technology of Obesity and MetabolismCampinasBrazil
  3. 3.Department of Surgery, Diabetic Surgery UnitState University of Campinas, UNICAMPCampinasBrazil

Personalised recommendations